I think what cynic is saying is this is undervalued even with the sector correction. Jason's latest target is 28% lower than last year but not 40%. Projected revenues are high enough to support more than a $500M market cap even with the slow trial. If FDA grants an early closure then this goes to the top of the target range or higher. That's at least $18 to $20. Bottom should be $9.00 right now with slow trial so anything below $9.50 is a strong buy if you're an investor. If a trader anything goes. Buy/sell the volatility.